---
document_datetime: 2025-12-05 14:06:00
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/voraxaze-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: voraxaze-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.3864667
conversion_datetime: 2025-12-29 20:57:51.336514
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Voraxaze

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | A.ADMINISTRATIVECHANGES-A.1 Change | 05/12/2025                          |                                          | SmPC,                           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000314574                       | in the name and/or address of the marketing authorisation holder - Accepted                                                                                                                                           |            |     | Labelling and PL   |                                                                                                                                                                                                                                            |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000291658   | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Other variation - Accepted                                                                                                           | 08/09/2025 | N/A |                    |                                                                                                                                                                                                                                            |
| Annual reassessment-H/ EMA/S/0000245171 | 3rd annual re-assessment.                                                                                                                                                                                             | 24/07/2025 |     |                    | TheCHMP,havingreviewedtheevidenceof compliance with the specific obligations and the impactofthedatasubmittedbytheMAHonthe benefit/riskprofileofthemedicinalproduct, concluded thatmarketing authorisationofVoraxaze should be maintained. |
| Variation type IB / EMA/VR/0000282479   | B.1.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturingprocessoftheactive substance-B.I.b.2.a Minor changes to an approved test procedure- Accepted | 22/07/2025 | N/A |                    |                                                                                                                                                                                                                                            |
| VariationtypeIB/ EMA/VR/0000281027      | B.II.FINISHEDPRODUCT-B.II.zOther variation - Accepted                                                                                                                                                                 | 18/07/2025 | N/A |                    |                                                                                                                                                                                                                                            |
| Variation type IB / EMA/VR/0000272959   | B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance-B.I.a.4.zOthervariation- Accepted                                                                                 | 13/06/2025 | N/A |                    |                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000265525   | A.5Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites)-A.5.bThe activities for which the manufacturer/importer is responsible do not include batch release -   | 10/04/2025   | N/A   |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|